Kathy Lennon
About Kathy Lennon
Kathy Reape is the Chief Medical Officer with extensive experience in clinical development and regulatory approvals, known for her role in the FDA approval of LUXTURNA, the first gene therapy for a genetic disease.
Chief Medical Officer Kathy Reape
Kathy Reape currently holds the position of Chief Medical Officer. In her role, she oversees the medical and clinical operations, guiding strategy and ensuring compliance with regulatory requirements. Her extensive experience in the pharmaceutical and biotech industry brings valuable insight and leadership to the organization.
Kathy Reape Education and Medical Expertise
Kathy Reape obtained her undergraduate degree and her M.D. from the University of Pennsylvania. She completed her internship and residency at the University of Florida and the University of Medicine and Dentistry of New Jersey. Her educational background laid a strong foundation for her expertise in medical science and clinical practices.
Previous Roles of Kathy Reape
Before her current position, Kathy Reape served as the Chief Medical Officer at Spark Therapeutics. She significantly contributed to the company's efforts, playing a pivotal role in the U.S. FDA approval and EMA marketing authorization of LUXTURNA, the first FDA-approved gene therapy for a genetic disease. Her leadership in innovative therapeutic developments is widely recognized.
Kathy Reape at Allergan and Actavis
Kathy Reape also held the position of senior vice president of clinical development at Allergan and Actavis. In this capacity, she focused on global brands research and development. Her work involved leading clinical trials and ensuring the efficacy and safety of new pharmaceutical products on a global scale.